Black Diamond Therapeutics (BDTX) Long-Term Investments (2020)

Black Diamond Therapeutics (BDTX) posted Long-Term Investments of $140.5 million for Q2 2020.

Black Diamond Therapeutics (BDTX) Long-Term Investments (2020) Analysis & Trends

Black Diamond Therapeutics' Long-Term Investments history runs 1 years deep, the most recent figure standing at $140.5 million for Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 505,194.89
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 5.75 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 9.79 Bn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Black Diamond Therapeutics 99.59 Mn -18.67 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2020 140.52 Mn